In the latest post on the the IVI-sponsored Health Affairs blog series, Erica Lietzan takes a look at the recent Supreme Court ruling on Sandoz v. Amgen, examining premarket patent litigation, patent resolution process, state law influence, and the impact of the SCOTUS ruling itself.
About the Health Affairs/IVI Blog Series: Drugs and Medical Innovation
In partnership with Health Affairs, IVI is proud to sponsor the “Drugs and Medical Innovation” blog series. On an ongoing basis, articles in this series will explore topics such as value-based reimbursement, drug policy and pricing, balancing short-term access against long-term rates of innovation, and other relevant issues. Our goal is to create an open forum for sharing ideas and debating issues in these areas, extending the discussion to a broader audience.